152 results on '"Dubruille V"'
Search Results
2. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas
3. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience
4. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma
5. P56 - Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation: COMPARABLE OUTCOMES AMONG ADULT PATIENTS ALLOTRANSPLANTED FOR MYELODYSPLASTIC SYNDROME USING HAPLOIDENTICAL, MATCHED UNRELATED OR MATCHED SIBLING DONORS: A SINGLE-CENTER STUDY.
6. Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation
7. Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier
8. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center
9. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity
10. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation
11. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation
12. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients
13. FEASABILITY OF A SEQUENTIAL CONDITIONING REGIMEN COMBINING CLOFARABINE/CYTARABINE CHEMOTHERAPY FOLLOWED BY A FLUDARABINE/CYCLOPHOSPHOMIDE/ATG-BASED RIC REGIMEN BEFORE ALLO-SCT IN ADULTS WITH PRIMARY/RELAPSED REFRACTORY MDS/AML: A PILOT STUDY: PH-AB260
14. Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy
15. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
16. Safety and efficacy of rituximab in steroid-refractory chronic GVHD
17. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors
18. Fludarabine, low-dose busulfan and antithymocyte globulin compared to fludarabine and low-dose TBI for reduced-intensity conditioning prior to allogeneic stem cell transplantation in patients with lymphoid malignancies: P968
19. Mantle cell lymphoma and autologous stem cell transplantation: no difference in term of outcome regarding the use or not of TBI in the conditioning: P861
20. Characterization of peripheral blood stem cell grafts mobilized by G-CSF and plerixafor in comparison to G-CSF alone: O380
21. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [F] FDG-PET diffuse large B-cell lymphoma patients
22. Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors
23. PF651 POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN A REAL LIFE SETTING: A SINGLE CENTER RETROSPECTIVE STUDY
24. PB2146 SINGLE AGENT DARATUMUMAB IN VERY ADVANCED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SINGLE CENTER RETROSPECTIVE STUDY
25. PS1046 FLT3 LIGAND PLASMA LEVELS HAVE NO IMPACT ON OUTCOMES AFTER ALLOTRANSPLANT IN ACUTE LEUKEMIA
26. Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death
27. 1018P - Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death
28. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
29. Safety and efficacy of rituximab in steroid-refractory chronic GVHD
30. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity
31. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation
32. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients
33. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors
34. Design and first interim analysis of a randomized phase III trial comparing imatinib versus imatinib (IM) based combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase
35. Zygomycosis after Prolonged Use of Voriconazole in Immunocompromised Patients with Hematologic Disease: Attention Required
36. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.
37. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
38. Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
39. Quad-class exposed/refractory myeloma is associated with short survival.
40. Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen.
41. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
42. Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
43. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
44. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
45. Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant.
46. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
47. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
48. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
49. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
50. Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.